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Background: In accordance with international guidelines, primary antifungal treatment (AFT) 
of candidemia with echinocandins has been nationally recommended in Denmark since 2009. 
Our nationwide cohort study describes the management of candidemia treatment focusing on the 
impact of prophylactic AFT on species distribution, the rate of adherence to the recommended 
national guidelines for AFT, and the effect of AFT on patient outcomes.
Materials and methods: Incident candidemia cases from a 2-year period, 2010–2011, were 
included. Information on AFT was retrospectively collected from patient charts. Vital status 
was obtained from the Danish Civil Registration System. HRs of mortality were reported with 
95% CIs using Cox regression.
Results: A total of 841 candidemia patients was identified. Prior to candidemia diagnosis, 19.3% 
of patients received AFT (162/841). The risk of non-albicans candidemia increased after prior 
AFT (59.3% vs 45.5% among nontreated). Echinocandins as primary AFT were given for 44.2% 
(302/683) of patients. Primary treatment with echinocandins resulted in adequate treatment in 
a higher proportion of patients (97.7% vs 72.1%) and was associated with lower 0- to 14-day 
mortality compared with azole treatment (adj. HR 0.76, 95% CI: 0.55–1.06). Significantly lower 
0- to 14-day mortality was observed for patients with Candida glabrata and Candida  krusei 
with echinocandin treatment compared with azole treatment (adj. HR 0.50, 95% CI: 0.28–0.89), 
but not for patients with Candida  albicans or Candida  tropicalis.
Conclusion: The association shown between prior AFT and non-albicans species underlines 
the importance of treatment history when selecting treatment for candidemia. Compliance with 
national recommendations was low, but similar to previously reported international rates. Primary 
treatment of candidemia with echinocandins compared with azoles yielded both a higher propor-
tion of adequately treated patients and improved mortality rates. This real-life setting supports 
guidelines recommendation, and further focus on compliance with these seems warranted.
Keywords: candidemia, candida, antifungal treatment, echinocandin, azole, Candida albicans, 
Candida glabrata
Introduction
Management of candidemia is challenging due to suboptimal diagnostics and com-
plex protocols for prophylactic, pre-emptive, empirical, and targeted treatments of 
different patient categories. The first guidelines from the Infectious Disease Society 
of America (IDSA) for the management of candidemia were published in 20001 and 
updated in 2009 as well as in 2016.2,3 The first national treatment recommendations 
were released in 2004 (Danish Pharmaceutical Product information, www.dli.dk, www.
pro.medicin.dk). Recommendations were revised annually, and in 2009, echinocandins 
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became the primary choice of antifungal treatment (AFT) 
with amphotericin B listed as  alternative; for children and 
hemodynamically stable patients, azoles could still be used. 
Mandatory National Danish Guidelines for hospital use of 
antifungals came in 2012 from The Danish Council for the 
Use of Expensive Hospital Medicine.4 Since then, echino-
candins have been the first choice for initial treatment with 
de-escalation according to susceptibility patterns. Thus, the 
Danish guidelines followed the international recommenda-
tions by replacing azoles with echinocandins as first-line rec-
ommendation for the treatment of candidemia.2,5–7 Denmark 
has a high and increasing proportion of Candida glabrata.8,9 
Thus, the shift to echinocandins was motivated by 1) the 
increasing incidence of the more resistant Candida species 
such as C. glabrata and Candida  krusei and 2) the possible 
superior efficacy of echinocandins against C. albicans.10
Guidelines are based on randomized trials,10–14 but results 
from “real-life” settings with assorted patient populations 
have been more diverse and guidelines more challenging 
to verify.15–19 Moreover, adherence to guidelines and the 
clinical effect of AFT have not previously been explored in 
a nationwide setting. Therefore, this cohort study aimed to 
describe the management of candidemia, including impact 
of prior AFT on species distribution, adherence to national 
recommendations, and clinical outcomes.
Materials and methods
setting, study population, and data 
collection
This study included all incident unique cases of candidemia 
among adults ≥16 years old in Denmark between 2010 and 
2011. Patients were identified as part of an ongoing national 
fungemia surveillance program.20
Information regarding department responsible for the 
candidemia diagnosis and AFT was retrospectively collected 
from patient charts by local clinical microbiologists. Treat-
ment information included the following: timing related to 
blood culture collection (BCC) date, dosage, and duration 
of initial and subsequent antifungal therapies.
The Danish healthcare system provides health care for 
all citizens free of charge.
Definitions
Polyfungal cases, defined as two or more Candida species 
present in blood cultures within 48 hours, were included in 
the analyses. Polyfungal cases with ≥48 hours between spe-
cies isolation were excluded due to complications in inter-
pretation of adequate treatment and follow-up time (n=15). 
Prior, initial, and secondary AFT was categorized as azoles 
(96.2%–99.1% fluconazole), echinocandins (88.6%–95.5% 
caspofungin, 4.5%–11.4% anidulafungin), and amphotericin 
B. De-escalation of AFT was defined as a change from echi-
nocandins or amphotericin B to azoles or from amphotericin 
B to echinocandins. Escalation of treatment was defined as a 
change in the opposite direction. Adequate AFT was assessed 
according to antifungal susceptibility testing.
Microbiology
Information on species identification and susceptibility was 
retrieved from the National Mycology Reference Laboratory 
at Statens Serum Institut, Copenhagen, Denmark. Procedures, 
species distribution, and susceptibility patterns for isolates 
have been described elsewhere.8 Antifungal susceptibility 
testing was performed according to available European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) 
breakpoints and epidemiological cutoff values (ECOFF).21
Mortality
Mortality data were obtained from The Danish Civil Registra-
tion System, in which the vital status, including death and 
emigration, of Danish citizens is registered and updated daily. 
Different time intervals were used to estimate treatment effi-
cacy. First, for AFT given prior to the BCC date, mortality at 
day 7 after BCC was used as a marker for effectiveness. This 
was chosen as the period influence on mortality is shorter for 
AFT given prior to BCC. Second, for AFT given after BCC 
date, mortality at day 14 was used as a marker of targeted 
therapy given the standard recommendation of 14 days’ dura-
tion of therapy. In addition, 30-day and 1-year mortality was 
assessed. Subanalysis was performed for C. glabrata and 
C. krusei to investigate the effect of treatment with different 
antifungal compounds for these more common species, which 
harbor intrinsic resistance.
ethics approval
Data collection was approved by the Danish Health authori-
ties (Journal no 3-3013-364/1/) and the Danish Data Protec-
tion Agency (Journal no 2004-54-1627).
statistical analyses
Statistical analyses were carried out in Stata®, vs 14 (Stata-
Corp). Quantitative variables were reported as median and 
IQR; qualitative variables as number (%). Prevalence propor-
tions were reported with 95% CIs. HRs for treatment effects 
on mortality was assessed using Cox regression with 95% 
CIs. Directed acyclic graphs were used to assess minimal 
sufficient adjustment sets for estimating the total effect of 
treatment on mortality (Figures S2 and S3).
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Results
candidemia episodes
A total of 841 primary cases of candidemia in adults was 
included (Figure S1). The median age was 67 years (IQR 
58–76) and 60.5% were males.
species distribution, department, and 
prior  aFT
Species distribution varied according to the department where 
the candidemia diagnosis occurred. Non-albicans species 
accounted for the majority of cases in medicine (55.0%) and 
hematology (75.0%) (Figure 1, overall species distribution in 
Table S1). AFT was given prior to BCC in 19.3% (162/841) 
of all patients. The proportion of patients receiving AFT 
prior to BCC varied across departments, lowest in medicine 
(7.7% [13/169]), and highest in hematology (46.9% [8/32]) 
(Figure 1).
The proportion of C. albicans was lower in patients with 
prior AFT, most evident for the echinocandins compared with 
patients without prior AFT (27.3% vs 54.5%; Table 1). The 
proportion of C. krusei was substantially higher in patients 
with prior AFT ([12.9% for azoles and 9.1% for echinocan-
dins] vs 2.2% without prior AFT). Similarly, C. glabrata 
was more prevalent in patients with prior AFT, especially 
evident for echinocandins (36.4% vs 28.0%). The association 
between prior AFT and the proportion of C. albicans was 
also observed at the department level except from the ICU 
and medicine (Figure 1). Prior AFT was given for >7 days in 
39.5% (64/162) of the treated patients and revealed a similar 
trend on species distribution as described above.
aFT after blood culture
Following BCC, 81.2% of patients received AFT. Among 
patients who survived until the results of blood cultures 
became available, 92.5% (664/718) received AFT. The rec-
ommendation of echinocandins as first-line treatment choice 
was followed in 44.2% (Table 2). Azoles were the main drug 
of choice (52.4%, 358/682) except in the Department of 
Hematology in which 56.7% (17/30) received echinocandins. 
Overall, the primary AFT was adequate in 84.4% (95% CI: 
81.4–87.0). Level of adequate AFT ranged from 72.1% (95% 
CI: 67.1–76.7) for patients treated with azoles to 97.7% 
(95% CI: 95.3–99.1) for treatment with echinocandins and 
100% (95% CI: 85.2–100) for treatment with amphotericin 
B (Figure 2).
Change of treatment to a second antifungal agent occurred 
in 37.6% (257/684) of treated patients after a median duration 
of 2 days of the first AFT. Escalation of AFT from azoles to 
echinocandins or amphotericin B was seen more often than 
change in the opposite direction (55.3%, 142/257). Overall, 
96.1% (247/257) of second-line choices were adequate ( Figure 
2). The recommended de-escalation from echinocandins to 
azoles according to susceptibility occurred in 103 of 148 
patients (69.6%) infected with susceptible species surviving 
≥5 days (making the patients eligible for treatment change). 
Median duration of treatment among survivors (≥14 days) was 
Figure 1 species distribution and prior aFT by hospital department at the time of candidemia diagnosis.
Abbreviation: aFT, antifungal treatment.
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15 (IQR 13–20) days. Dosing information was available for 
87.9%. For patients receiving primary treatment with fluco-
nazole, 50.8% (133/262) received the recommended loading 
dose of 800 mg. For patients receiving echinocandins, a load-
ing dose of either 70 mg caspofungin or 200 mg anidulafungin 
was administered in 81.7% (215/263) of patients
Mortality and treatment
Mortality status was available for 99.5% (837/841). A notable 
proportion of patients died before blood culture results 
became available (14.2%, 119/837). These patients were 
older and more frequently admitted to the ICU; however, 
fewer of these patients had a central venous catheter (CVC) 
or received total parenteral nutrition compared with the 
remainder patients.
Table 1 species distribution according to prior  aFT
No prior AFT
N=679
% (95% CI)
Prior AFT
N=162
% (95% CI)
Prior azolea
N=132
% (95% CI)
Prior echinocandinsb
N=22
% (95% CI)
Species identification
C. albicans 54.5 (50.7–58.3) 40.7 (33.1–48.7) 43.2 (34.6–52.1) 27.3 (10.7–50.2)
C. glabrata 28.0 (24.6–31.5) 31.5 (24.4–39.2) 31.8 (24.0–40.5) 36.4 (17.2–59.3)
C. krusei 2.4 (1.4–3.8) 11.7 (7.2–17.7) 12.9 (7.7–19.8) 9.1 (1.1–29.2)
Candida tropicalis 3.7 (2.4–5.4) 3.1 (1.0–7.1) 3.0 (0.8–7.6) 4.5 (0.1–22.8)
Candida parapsilosis 2.8 (1.7–4.3) 2.5 (0.7–6.2) 1.5 (0.2–5.4) 9.1 (1.1–29.2)
Othersc 4.4 (3.0–6.2) 6.8 (3.4–11.8) 4.5 (1.7–9.6) 9.1 (1.1–29.2)
Polyfungal 4.1 (2.8–5.9) 3.7 (1.4–7.9) 3.0 (0.8–7.6) 4.5 (0.1–22.8)
Notes: aOne hundred twenty-seven cases received fluconazole, three cases received posaconazole, and two cases received voriconazole. bTwenty-one cases received 
caspofungin and one case received anidulafungin. cOther species, ie, Candida dubliniensis, Candida lusitaniae, and Candida kefyr (see Table s1).
Abbreviation: aFT, antifungal treatment.
Table 2 aFT according to hospital department at the time of 
candidemia diagnosis
Total
No (%)
ICU
No (%)
Hematology
No (%)
Initial aFT after Bcc n=683 n=305 n=30
azolea 358 (52.4) 164 (53.8) 9 (30.0)
echinocandinsb 302 (44.2) 135 (44.3) 17 (56.7)
amphotericin B 23 (3.4) 6 (2.0) 4 (13.3)
adequate 1. aFT 576 (84.3) 262 (85.9) 25 (83.3)
second aFT n=257 n=115 n=12
azolec 113 (44.0) 47 (40.9) 1 (8.3)
echinocandinsd 123 (47.9) 61 (53.0) 5 (41.7)
amphotericin B 21 (8.2) 7 (6.1) 6 (50.0)
adequate 2. treatment 247 (96.1) 112 (97.4) 11 (91.7)
Notes: aThree hundred fifty-five cases received fluconazole and three cases 
received voriconazole. bTwo hundred seventy-eight cases received caspofungin and 
24 cases received anidulafungin. cOne hundred eleven cases received fluconazole 
and two cases received voriconazole. cOne hundred nine cases received caspofungin 
and 14 cases received anidulafungin.
Abbreviations: aFT, antifungal treatment; Bcc, blood culture collection; IcU, 
intensive care unit.
A sum of 18.5% did not receive AFT after BCC and 
20.6% (32/155) of these survived ≥14 days after BCC. 
Patients surviving ≥14 days without treatment did not differ 
from the total cohort of candidemia.
The overall 7- and 14-day mortality among primary 
cases of candidemia was 23.7% (198/837) and 33.7% 
(281/835), increasing to 43.3% (362/8337) at day 30 and 
62.1% (520/837) at 1 year follow-up. Treatment after BCC 
was associated with a significantly lower 14-day mortality 
compared with nontreated patients (adj. HR 0.12, 95% CI: 
0.10–0.16, Table 3). Initial treatment with echinocandins was 
associated with lower 14-day mortality compared with azole 
treatment (adj. HR 0.76, 95% CI: 0.55–1.06), and the same 
trend was seen at both 30 days and 1 year follow-up (Table 3). 
The association was more pronounced for C. glabrata and 
C.  krusei cases at all time points (14-day mortality adj. HR 
0.50, 95% CI: 0.28–0.89), whereas no difference was observed 
for C. albicans and C. tropicalis cases (14-day mortality adj. 
HR 1.00, 95% CI: 0.65–1.55). Adequate initial treatment was 
associated with lower 14-day mortality (adj. HR 0.80, 95% CI: 
0.53–1.19), whereas for C. glabrata and C. krusei adequate 
treatment was associated with lower mortality at all time 
points (14-day mortality adj. HR 0.62, 95% CI: 0.36–1.08).
Discussion
This cohort study evaluated AFT management practices 
and outcomes in a nationwide clinical setting. Adherence to 
AFT guidelines following BCC was low as less than half of 
the patients received echinocandins as initial treatment. Our 
findings indicated that initial treatment with echinocandins 
resulted in a greater number of patients achieving sufficient 
levels of treatment and a lower mortality rate compared with 
patients treated with azoles. This decrease in mortality was 
significant among patients with C. glabrata and C. krusei.
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A total of 21% of the candidemia patients received prior 
AFT, which is similar to previously published studies (12%–
21%).22–26 Previous studies also demonstrated that prior AFT 
was associated with more non-albicans species.27,28 Data from 
the hematology department in our data supported this, where 
46.9% received prior AFT and 25.0% of the candidemia isolates 
were C. albicans. More frequent caspofungin exposure was also 
associated with Candida strains with reduced caspofungin sus-
ceptibility in a matched case–control hematological patients.29 
Likewise, prophylactic AFT altered subsequent colonization 
species toward non-albicans species in a randomized controlled 
trial.30 A recent Danish study examined colonization species 
after AFT for candidemia and showed a change toward a higher 
proportion of strains with intrinsic resistance to azoles following 
≥7 days of fluconazole. Furthermore, an increase in acquired 
resistance to C. glabrata after both azole and echinocandin 
treatment was observed.31 The current study supports the 
evidence that prior AFT is associated with a greater propor-
tion of non-albicans at the patient level and at the department 
level comparing species distribution at the Department of 
Hematology where a high proportion of patients receive prior 
AFT with species distribution in departments with lower use 
of AFT prior to candidemia diagnosis. This association could 
not be confirmed comparing ICU, medicine, and surgery pos-
sible due to small sample size, but potentially also reflecting 
that other factors influence the species distribution including 
Figure 2 Proportion of patients receiving adequate treatment according to choice of initial antifungal agent.
Note: *100% of amphotericin B-treated cases were adequately treated in both initial and second aFT.
Abbreviation: aFT, antifungal treatment.
Initial AFT
Echinocandins
44.2%
Adequately
treated
97.7% 
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treated
27.9% Adequately
treated
72.1% 
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age, duration of prior AFT, and potential AFT prior to the cur-
rent hospitalization. Nevertheless, these findings underline the 
importance of information regarding prior AFT when selecting 
AFT for a subsequent candidemia.
The low adherence to the recommended guidelines of 
initial treatment with echinocandins (44.3%) is comparable 
with other studies that report using echinocandins as primary 
treatment in 17%–57% of patients with candidemia.16,18,22,23,28 
We are unaware of prior nationwide studies on the compliance 
with treatment recommendations. A study from 87 ICUs in 
France identified the compliance rate with IDSA or ESC-
MID guidelines as “rather poor,” given that 62.5% of ICU 
patients with proven invasive candidiasis (mainly candidemia) 
received echinocandins as primary treatment.19 We showed 
that treatment with echinocandins increased the proportion of 
adequately treated patients and that the overall proportion of 
candidemia patients receiving adequate treatment was higher 
than previously described (84.3% vs 57%–68%).18,32,33 Follow-
ing the completion of our study, mandatory National Guide-
lines for AFT were implemented in Denmark in 2012 and 
we cannot exclude that treatment practice has improved over 
time. However, the mandatory guidelines for AFT resemble 
the treatment recommendations from 2009 to 12 and except 
from one recent initiative to survey AFT with an antifungal 
stewardship programs in the capital region of Denmark, no 
specific focus have been targeted to AFT guidelines.
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Table 3 Treatment and mortality
Total
No (%)
Deaths
No (%)
Crude Cox
HR (95% CI)
Adjusted Cox
HR (95% CI)
0- to 7-Day mortality n=837 n=198
Prior antifungal treatment 162 (19.4) 33 (16.7) 0.80 (0.55–1.16) 1.24a (0.84–1.84)
Prior adequate treatment 92 (11.0) 18 (9.1) 0.78 (0.48–1.26) 1.12a (0.68–1.84)
0- to 14-Day mortality n=837 n=281
Treatment after Bc 683 (81.6) 160 (56.9) 0.13 (0.10–0.17) 0.12b (0.10–0.16)
Received treatment n=682 n=160
azole as primary treatment 357 (52.3) 89 (55.6) Ref Ref
echinocandins as primary treatment 302 (44.3) 62 (38.8) 0.79 (0.57–1.09) 0.76b (0.55–1.06)
amphotericin B as primary treatment 23 (3.4) 9 (5.6) 1.79 (0.90–3.56) 1.50b (0.74–3.07)
adequate initial aFT 576 (84.3) 131 (81.9) 0.81 (0.54–1.21) 0.80b (0.53–1.19)
0- to 14-Day mortality by species
C. glabrata or C. kruseic n=223 n=53
azole as primary treatment 93 (41.7) 27 (50.9) Ref Ref
echinocandins as primary treatment 122 (54.7) 22 (41.5) 0.57 (0.32–0.99) 0.50b (0.28–0.89)
amphotericin B as primary treatment 8 (3.6) 4 (7.6) 2.27 (0.79–6.49) 1.78b (0.58–5.41)
adequate initial aFT 134 (60.1) 28 (52.8) 0.70 (0.41–1.20) 0.62b (0.36–1.08)
C. albicans or C. tropicalisc n=374 n=88
azole as primary treatment 223 (59.6) 51 (58.0) Ref Ref
echinocandins as primary treatment 144 (38.5) 34 (38.6) 1.01 (0.65–1.55) 1.00b (0.65–1.55)
amphotericin B as primary treatment 7 (1.9) 3 (3.4) 2.51 (0.78–8.04) 2.30b (0.71–7.46)
0- to 30-Day mortalityc n=682 n=239
azole as primary treatment 357 (52.4) 129 (54.0) ref ref
echinocandins as primary treatment 302 (44.3) 101 (42.3) 0.89 (0.68–1.15) 0.86b (0.66–1.12)
amphotericin B as primary treatment 23 (3.4) 9 (3.8) 1.24 (0.63–2.44) 1.04b (0.52–2.07)
adequate initial aFT 576 (84.3) 197 (82.4) 0.83 (0.60–1.16) 1b (omitted)
0- to 30-Day mortality by species
C. glabrata or C. kruseic n=223 n=78
azole as primary treatment 93 (41.7) 39 (50.0) Ref Ref
echinocandins as primary treatment 122 (54.7) 35 (44.9) 0.60 (.038–0.95) 0.56b (0.35–0.90)
amphotericin B as primary treatment 8 (3.6) 4 (5.1) 1.55 (0.56–4.35) 1.26b (0.44–3.65)
adequate initial aFT 134 (60.1) 42 (53.9) 0.71 (0.45–1.11) 0.66b (0.42–1.04)
C. albicans or C. tropicalisc n=374 n=135
azole as primary treatment 223 (59.6) 76 (56.3) Ref Ref
echinocandins as primary treatment 144 (38.5) 56 (41.5) 1.15 (0.81–1.62) 1.14b (0.80–1.60)
amphotericin B as primary treatment 7 (1.9) 3 (2.2) 1.65 (0.52–5.23) 1.49b (0.47–4.78)
0- to 365-Day mortalityc n=682 n=390
azole as primary treatment 357 (52.4) 199 (51.0) Ref Ref
echinocandins as primary treatment 302 (44.3) 177 (45.4) 1.03 (0.84–1.26) 0.99b (0.81–1.22)
amphotericin B as primary treatment 23 (3.4) 14 (3.6) 1.22 (0.71–2.10) 0.97b (0.55–1.69)
adequate initial aFT 576 (84.3) 318 (81.5) 0.75 (0.58–0.97) 1b (omitted)
0- to 365-Day mortality by species
C. glabrata or C. kruseic n=223 n=141
azole as primary treatment 93 (41.7) 64 (45.4) Ref Ref
echinocandins as primary treatment 122 (54.7) 70 (49.7) 0.71 (0.51–1.00) 0.66b (0.46–0.93)
amphotericin B as primary treatment 8 (3.6) 7 (5.0) 1.71 (0.79–3.74) 1.44b (0.65–3.18)
adequate initial aFT 134 (60.1) 79 (56.0) 0.74 (0.53–1.04) 0.70b (0.50–0.98)
C. albicans or C. tropicalisc n=374 n=203
azole as primary treatment 223 (59.6) 108 (53.2) Ref Ref
echinocandins as primary treatment 144 (38.5) 90 (44.3) 1.38 (1.04–1.82) 1.37b (1.03–1.81)
amphotericin B as primary treatment 7 (1.9) 5 (2.5) 1.98 (0.81–4.85) 1.82b (0.69–4.27)
Notes: asee supplement Dag1: adjusted for fungal treatment after blood sampling, hematologic disease, and abdominal surgery. bsee supplement Dag2: adjusted for fungal 
treatment before blood sampling, hematologic disease, and abdominal surgery. cOnly patients receiving treatment were included.
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Evaluation of treatment effect on outcome in candidemia 
patients is complicated and especially comparing patients 
receiving AFT with nontreated patients carries a risk of 
substantial bias. Surviving long enough to receive treat-
ment, as well as being selected for treatment, highlights 
a subgroup of patients with a better presumptive survival 
expectancy. While this issue is frequently unaccounted for 
in candidemia evaluations, it is routinely accounted for in 
oncology research investigating survival of responders to 
nonresponders.34 We included the analysis of treated cases vs 
nontreated cases at day 14 to illustrate the extremely (unre-
alistic) advantageous treatment effect rates (HR 0.13, 95% 
CI: 0.10–0.16) compared with the nontreated. However, we 
find the comparison of treatment vs nontreatment unusable 
for further considerations.
We noted a lower 14-day mortality among patients receiv-
ing echinocandins compared with patients receiving azoles, 
which was further substantiated by a lower mortality rate 
among patients with C. glabrata or C. krusei. Such superior 
efficacy against intrinsically more azole-resistant species is 
expected from a mycology point of view and supports the 
recommendation of echinocandins as initial treatment choice 
in a setting with high incidence of C. glabrata, such as in 
Denmark, the USA, Scotland, Belgium, France, Finland, Swe-
den, and Australia.23,35–39 Lower mortality among C. glabrata 
cases treated with echinocandins was also found in a previ-
ous Danish study.40 In contrast, no correlation was found on 
primary AFT and mortality in a single-center Italian study in 
which only 6.9% were diagnosed with C. glabrata16 nor did 
the prior French ICU study show any difference in mortality 
on primary AFT with 16.6% C. glabrata.19 Furthermore, the 
2010–2011 CANDIPOP project from 29 hospitals in Spain 
found no overall difference41 or among the 13.4% of cases 
with C. glabrata.15 Another important factor is a possible 
greater number of comorbidities among C. glabrata cases 
vs other species. This would reduce the attributable mortal-
ity of candidemia and consequently dilute the efficacy of 
echinocandins; therefore, our findings are adjusted for key 
comorbidities. A patient-level quantitative review of seven 
randomized trials for the treatment of invasive candidiasis 
showed improved survival after use of echinocandins.13 No 
new randomized controlled trials of AFT have been per-
formed since the introduction of echinocandins as primary 
treatment for candidemia in the 2012 guidelines. The gap 
between results from RCT and verification in epidemiologic 
studies highlights the importance of “real-life” evaluations to 
inform the next iterations of National Guidelines.
There are limitations to our data including possible dif-
ferences in data collection as multiple doctors contributed. 
Survey forms were used to minimalize this issue. Another 
limitation is the insufficient data on CVC removal and kidney 
function. Due to frequent changes in treatment selection and 
transfer of patients, between-hospital data on dosing were 
missing in 87.9% of the patients. On the contrary, the Dan-
ish personal security number system insured the inclusion 
of incident candidemia patients and eliminated the poten-
tial for duplicate cases. Finally, due to the lack of detailed 
clinical data regarding severity of the underlying disease, the 
potential bias was not included in our analysis. As severely 
ill patients are likely more often treated with echinocandins 
rather than fluconazole, a likely consequence is that we may 
have underestimated the superiority of the echinocandins.
In conclusion, this is the first study to evaluate AFT 
in a national setting. Our findings support and extend the 
knowledge on the impact of prior AFT on species distribu-
tion. Echinocandins were favorable both with regard to the 
proportion of adequately treated patients and prognosis. Thus, 
our findings support national guideline recommendations 
of echinocandins as primary treatment for candidemia in 
Denmark. Further nationwide studies assessing enforcement 
of recommended guideline adherence and effect of AFT are 
needed for comparable and updated data.
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Supplementary materials
Table S1 species distribution
Species No. %
C. albicans 437 52.0
C. glabrata 241 28.7
C. krusei 35 4.2
C. tropicalis 30 3.6
C. parapsilosis 23 2.7
C. dubliniensis 15 1.8
C. lusitaniae 6 0.7
C. kefyr 5 0.6
C. norvegensis 3 0.4
C. guilliermondii 3 0.4
C. orthopsilosis 2 0.2
C. pelliculosa 2 0.2
C. inconspicua 1 0.1
C. palmioleophila 1 0.1
S. cerevisiae 3 0.4
Polyfungal 34 4.0
Total 841 100.0
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Figure S1 Flow chart of the study population.
Figure S2 Directed acyclic graphs (Dag s): Prior antifungal treatment and 7-day 
mortality.
Figure S3 Directed acyclic graphs (Dags) showing antifungal treatment after 
blood culture collection and 14-day mortality.
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